Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis

Molecular Therapy

Volumn 21, Issue 11, 2013, Pages 2043-2053

  Ben Yebdri, Fethia ^a   Van Grevenynghe, Julien ^a,b   Tang, Vera A ^c   Goulet, Marie Line ^a   Wu, Jian Hui ^a   Stojdl, David F ^c   Hiscott, John ^a,b   Lin, Rongtuan ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Division of Infectious Diseases   (United States)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; INTERFERON; INTERFERON REGULATORY FACTOR 3; LIPOCORTIN 5; PROTEIN BCL 2; TRIPTOLIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER INHIBITION; CELL LINE; CELL STRAIN PC3; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG POTENCY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ONCOLYSIS; ONCOLYTIC VIROTHERAPY; PROSTATE CANCER; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; SURVIVAL TIME; TRANSCRIPTION INITIATION; TUMOR CELL DESTRUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION;

ANIMALIA; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DITERPENES; EPOXY COMPOUNDS; FEMALE; HEK293 CELLS; HUMANS; INTERFERONS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PHENANTHRENES; SIGNAL TRANSDUCTION; VESICULAR STOMATITIS INDIANA VIRUS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887450116     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.187     Document Type: Article

References (50)

1. Kaur, B, Cripe, TP and Chiocca, EA (2009). "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther 9: 341-355.
2. Meerani, S (2010). Oncolytic viruses in cancer therapy. Eur J Sci Res 40: 156-171.
3. Russell, SJ, Peng, KW and Bell, JC (2012). Oncolytic virotherapy. Nat Biotechnol 30: 658-670.
4. Lichty, BD, Power, AT, Stojdl, DF and Bell, JC (2004). Vesicular stomatitis virus: reinventing the bullet. Trends Mol Med 10: 210-216.
5. Stojdl, DF, Lichty, BD, tenOever, BR, Paterson, JM, Power, AT, Knowles, S et al. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
6. Stojdl, DF, Lichty, B, Knowles, S, Marius, R, Atkins, H, Sonenberg, N et al. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821-825.
7. Barber, GN (2005). VSV-tumor selective replication and protein translation. Oncogene 24: 7710-7719.
8. Nguy, TL, Abdelbary, H, Arguello, M, Breitbach, C, Leveille, S, Diallo, JS et al. (2008). Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci USA 105: 14981-14986.
9. Tumilasci, VF, Olie, S, Nguy, TL, Shamy, A, Bell, J and Hiscott, J (2008). Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. J Virol 82: 8487-8499.
10. Alain, T, Lun, X, Martineau, Y, Sean, P, Pulendran, B, Petroulakis, E et al. (2010). Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci USA 107: 1576-1581.
11. Schache, P, Glevik, E, StRer, N, Woller, N, Malek, N, Zender, L et al. (2009). VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1. Gene Ther 16: 849-861.
12. Leveille, S, Samuel, S, Goulet, ML and Hiscott, J (2011). Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy. Cancer Gene Ther 18: 435-443.
13. Zhou, ZL, Yang, YX, Ding, J, Li, YC and Miao, ZH (2012). Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. Nat Prod Rep 29: 457-475.
14. Wu, Y, Wang, Y, Zhong, C, Li, Y, Li, X and Sun, B (2003). The suppressive effect of triptolide on experimental autoimmune uveoretinitis by down-regulating Th1-type response. Int Immunopharmacol 3: 1457-1465.
15. Wang, Y, Jia, L and Wu, CY (2008). Triptolide inhibits the differentiation of Th17 cells and suppresses collagen-induced arthritis. Scand J Immunol 68: 383-390.
16. Wei, X, Gong, J, Zhu, J, Wang, P, Li, N, Zhu, W et al. (2008). The suppressive effect of triptolide on chronic colitis and TNF-alpha/TNFR2 signal pathway in interleukin-10 deficient mice. Clin Immunol 129: 211-218.
17. Kitzen, JJ, de Jonge, MJ, Lamers, CH, Eskens, FA, van der Biessen, D, van Doorn, L et al. (2009). Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer 45: 1764-1772.
18. Kiviharju, TM, Lecane, PS, Sellers, RG and Peehl, DM (2002). Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res 8: 2666-2674.
19. Wong, KF, Yuan, Y and Luk, JM (2012). Tripterygium wilfordii bioactive compounds as anticancer and anti-inflammatory agents. Clin Exp Pharmacol Physiol 39: 311-320.
20. Lipsky, PE and Tao, XL (1997). A potential new treatment for rheumatoid arthritis: thunder god vine. Semin Arthritis Rheum 26: 713-723.
21. Qiu, D and Kao, PN (2003). Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs R D 4: 1-18.
22. Chen, BJ (2001). Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma 42: 253-265.
23. Wu, Y, Cui, J, Bao, X, Chan, S, Young, DO, Liu, D et al. (2006). Triptolide attenuates oxidative stress, NF-kappaB activation and multiple cytokine gene expression in murine peritoneal macrophage. Int J Mol Med 17: 141-150.
24. Premkumar, V, Dey, M, Dorn, R and Raskin, I (2010). MyD88-dependent and independent pathways of Toll-Like Receptors are engaged in biological activity of Triptolide in ligand-stimulated macrophages. BMC Chem Biol 10: 3.
25. Xiao, C, Zhou, J, He, Y, Jia, H, Zhao, L, Zhao, N et al. (2009). Effects of triptolide from Radix Tripterygium wilfordii (Leigongteng) on cartilage cytokines and transcription factor NF-kappaB: a study on induced arthritis in rats. Chin Med 4: 13.
26. Shamon, LA, Pezzuto, JM, Graves, JM, Mehta, RR, Wangcharoentrakul, S, Sangsuwan, R et al. (1997). Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from Tripterygium wilfordii. Cancer Lett 112: 113-117.
27. Pan, J (2010). RNA polymerase-an important molecular target of triptolide in cancer cells. Cancer Lett 292: 149-152.
28. Titov, DV, Gilman, B, He, QL, Bhat, S, Low, WK, Dang, Y et al. (2011). XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 7: 182-188.
29. Phillips, PA, Dudeja, V, McCarroll, JA, Borja-Cacho, D, Dawra, RK, Grizzle, WE et al. (2007). Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res 67: 9407-9416.
30. Yang, S, Chen, J, Guo, Z, Xu, XM, Wang, L, Pei, XF et al. (2003). Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2: 65-72.
31. Carter, BZ, Mak, DH, Shi, Y, Fidler, JM, Chen, R, Ling, X et al. (2012). MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia 26: 443-450.
32. Liu, Q (2011). Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol 11: 377-383.
33. Carter, BZ, Mak, DH, Schober, WD, McQueen, T, Harris, D, Estrov, Z et al. (2006). Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 108: 630-637.
34. Zhu, W, Hu, H, Qiu, P and Yan, G (2009). Triptolide induces apoptosis in human anaplastic thyroid carcinoma cells by a p53-independent but NF-kappaB-related mechanism. Oncol Rep 22: 1397-1401.
35. Yinjun, L, Jie, J and Yungui, W (2005). Triptolide inhibits transcription factor NFkappaB and induces apoptosis of multiple myeloma cells. Leuk Res 29: 99-105.
36. Jiang, XH, Wong, BC, Lin, MC, Zhu, GH, Kung, HF, Jiang, SH et al. (2001). Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene 20: 8009-8018.
37. Chen, Q, Lu, Z, Jin, Y, Wu, Y and Pan, J (2010). Triptolide inhibits Jak2 transcription and induces apoptosis in human myeloproliferative disorder cells bearing Jak2V617F through caspase-3-mediated cleavage of Mcl-1. Cancer Lett 291: 246-255.
38. Wang, Y, Lu, JJ, He, L and Yu, Q (2011). Triptolide (TPL) inhibits global transcription by inducing proteasome-dependent degradation of RNA polymerase II (Pol II). PLoS ONE 6: e23993.
39. Noser, JA, Mael, AA, Sakuma, R, Ohmine, S, Marcato, P, Lee, PW et al. (2007). The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol Ther 15: 1531-1536.
40. Bensaude, O (2011). Inhibiting eukaryotic transcription: Which compound to choose? How to evaluate its activity? Transcription 2: 103-108.
41. Samuel, S, Tumilasci, VF, Oliere, S, Nguy?, TL, Shamy, A, Bell, J et al. (2010). VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia. Mol Ther 18: 2094-2103.
42. Swanton, E, Savory, P, Cosulich, S, Clarke, P and Woodman, P (1999). Bcl-2 regulates a caspase-3/caspase-2 apoptotic cascade in cytosolic extracts. Oncogene 18: 1781-1787.
43. Carey, BL, Ahmed, M, Puckett, S and Lyles, DS (2008). Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J Virol 82: 12104-12115.
44. Ahmed, M, Cramer, SD and Lyles, DS (2004). Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 330: 34-49.
45. Le Boeuf, F, Diallo, JS, McCart, JA, Thorne, S, Falls, T, Stanford, M et al. (2010). Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 18: 888-895.
46. Prestwich, RJ, Errington, F, Diaz, RM, Pandha, HS, Harrington, KJ, Melcher, AA et al. (2009). The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 20: 1119-1132.
47. Yoon, MJ, Lee, HJ, Kim, JH and Kim, DK (2006). Extracellular ATP induces apoptotic signaling in human monocyte leukemic cells, HL-60 and F-36P. Arch Pharm Res 29: 1032-1041.
48. Deli, T and Csernoch, L (2008). Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors. Pathol Oncol Res 14: 219-231.
49. Zhou, H, Zhang, Y, Fu, Y, Chan, L and Lee, AS (2011). Novel mechanism of antiapoptotic function of 78-kDa glucose-regulated protein (GRP78): endocrine resistance factor in breast cancer, through release of B-cell lymphoma 2 (BCL-2) from BCL-2-interacting killer (BIK). J Biol Chem 286: 25687-25696.
50. Zhao, T, Yang, L, Sun, Q, Arguello, M, Ballard, DW, Hiscott, J et al. (2007). The NEMO adaptor bridges the nuclear factor-kappaB and interferon regulatory factor signaling pathways. Nat Immunol 8: 592-600.